- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00622908
Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis
March 4, 2015 updated by: Bausch & Lomb Incorporated
A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis
To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of bacterial conjunctivitis
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
270
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be at least one year of age.
- Must have signature of subject or legally authorized representative (if subject is under 18 years of age) on the informed Consent Form.
- Must have signature of subject on the Assent Form if subject is 6 to 17 years of age.
- Must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge (crusty or sticky eyelids) and redness in at least one eye. A minimum score of 1 should be present for discharge and a minimum score of 1 for either bulbar or palpebral conjunctival injection.
- Must have pinholed visual acuity equal to or better than 20/200 in both eyes. Age appropriate visual acuity testing was to be performed. Every effort was made to obtain a visual acuity measurement in children. If visual acuity was unobtainable in children, it was at the investigator's discretion to meet inclusion criteria.
- Must be willing to discontinue contact lens wear for the duration of the study.
- Must be willing to avoid disallowed medications during the study period.
- Must understand the scope of the study including completion of diary, be willing to follow instructions, and be able to make all required study visits.
- If a subject was a female of childbearing potential, she must utilize reliable contraceptive methods and have a negative pregnancy test.
Exclusion Criteria:
- Any uncontrolled systemic disease or debilitating disease.
- Use of topical ophthalmic solutions including tear substitutes within two hours before and during the study.
- Use of any ophthalmic topical anti-inflammatory agents within 48 hours before and during the study.
- Subjects likely to require antimicrobial therapy with any active respiratory tract infection, urinary tract infection, skin/soft tissue infection, or otitis media.
- Pregnant or nursing females.
- Known hypersensitivity to SS734 or to any of the ingredients in the study medications.
- Known hypersensitivity to fluoroquinolones or to any of the ingredients in the study medications.
- Ocular surgery (including laser surgery) in either eye within the past six weeks.
- Subjects with suspected viral or allergic conjunctivitis (i.e., severe itching or acute follicular conjunctivitis), or any other disease conditions that could interfere with the efficacy and safety evaluations of the study medication.
- Subjects with suspected iritis (i.e., smaller pupil, pain, and photophobia in infected eye).
- History of recurrent corneal erosion syndrome, either idiopathic or secondary to previous corneal trauma or dry eye syndrome.
- Use of any antibiotic within 72 hours of enrollment.
- Any active ulcerative keratitis, specifically any epithelial loss greater than punctate keratitis
- Participation in an ophthalmic drug or device research study within the 30 days prior to entry in this study.
- Subjects who were immune compromised.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ISV-403
ISV-403 0.6%
|
0.6% TID, 5 days
Other Names:
|
Placebo Comparator: Vehicle
Vehicle of ISV-403
|
Vehicle of ISV-403 TID, 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Resolution of Baseline Bacterial Conjunctivitis (Day 8 or 9)
Time Frame: Visit 3 - day 8 or 9
|
Resolution of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.
|
Visit 3 - day 8 or 9
|
Eradication of Baseline Pathogens (Day 8 or 9)
Time Frame: Visit 3 - Day 8 or day 9
|
Bacterial species eradication of baseline bacterial infection
|
Visit 3 - Day 8 or day 9
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Resolution of Baseline Bacterial Conjunctivitis Day 4 (+/- 1 Day)
Time Frame: Visit 2 - Day 4 (+/- 1 day)
|
The absence of conjunctival discharge, bulbar conjunctival injection and palpebral conjunctival injection.
|
Visit 2 - Day 4 (+/- 1 day)
|
Eradication of Baseline Pathogens Day 4 (+/- 1 Day)
Time Frame: Visit 2 - Day 4 (+/- 1 day)
|
Bacterial species eradication of baseline bacterial infection
|
Visit 2 - Day 4 (+/- 1 day)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- DeCory HH, Sanfilippo CM, Proskin HM, Blondeau JM. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6. PLoS One. 2020 Aug 25;15(8):e0237603. doi: 10.1371/journal.pone.0237603. eCollection 2020.
- Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675-85. doi: 10.2165/11536720-000000000-00000.
- Karpecki P, Depaolis M, Hunter JA, White EM, Rigel L, Brunner LS, Usner DW, Paterno MR, Comstock TL. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009 Mar;31(3):514-26. doi: 10.1016/j.clinthera.2009.03.010.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2004
Primary Completion (Actual)
June 1, 2005
Study Completion (Actual)
June 1, 2005
Study Registration Dates
First Submitted
February 14, 2008
First Submitted That Met QC Criteria
February 14, 2008
First Posted (Estimate)
February 25, 2008
Study Record Updates
Last Update Posted (Estimate)
March 24, 2015
Last Update Submitted That Met QC Criteria
March 4, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Eye Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Conjunctival Diseases
- Eye Infections, Bacterial
- Eye Infections
- Conjunctivitis
- Conjunctivitis, Bacterial
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Besifloxacin
Other Study ID Numbers
- 373 (Italian RSO http://osservazionali.agenziafarmaco.it)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Conjunctivitis
-
Laboratoires TheaCompletedPurulent Bacterial ConjunctivitisFrance
-
IVIEW Therapeutics Inc.CompletedAcute Bacterial ConjunctivitisChina
-
Bausch & Lomb IncorporatedCompletedAcute Bacterial Conjunctivitis
-
Bausch & Lomb IncorporatedCompletedAcute Bacterial Conjunctivitis
-
Azidus BrasilUnknownAcute Bacterial ConjunctivitisBrazil
-
ShireCompletedBacterial ConjunctivitisUnited States, Australia, Austria, Israel, Poland, Hungary, South Africa, Canada, Estonia, France, Italy, Spain, Puerto Rico
-
AllerganCompletedBacterial ConjunctivitisUnited States, India
-
Beijing Tongren HospitalZhuhai Essex Bio-Pharmaceutical Company Limited; Panacea TechnologiesUnknownBacterial ConjunctivitisChina
-
Merck Sharp & Dohme LLCCompletedBacterial ConjunctivitisUnited States
-
Alcon ResearchWithdrawn
Clinical Trials on ISV-403
-
Bausch & Lomb IncorporatedCompleted
-
Oncurious NVBeat Childhood CancerCompletedRelapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)United States
-
Bausch & Lomb IncorporatedCompleted
-
Bausch & Lomb IncorporatedCompletedAcute Bacterial Conjunctivitis
-
BioInvent International ABOxurionCompleted
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
-
AmgenCompleted
-
AmgenCompleted
-
Array Biopharma, now a wholly owned subsidiary...Completed
-
Array BioPharmaCompleted